Werewolf Therapeutics, Inc. (HOWL)
- Previous Close
2.0100 - Open
2.0500 - Bid 1.9500 x 200
- Ask 2.1100 x 200
- Day's Range
2.0200 - 2.0500 - 52 Week Range
1.5740 - 8.1940 - Volume
11,703 - Avg. Volume
198,276 - Market Cap (intraday)
88.278M - Beta (5Y Monthly) 0.46
- PE Ratio (TTM)
-- - EPS (TTM)
-1.3800 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.00
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
werewolftx.comRecent News: HOWL
View More
Performance Overview: HOWL
Trailing total returns as of 10/4/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: HOWL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: HOWL
View MoreValuation Measures
Market Cap
88.28M
Enterprise Value
-10.35M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.59
Price/Book (mrq)
0.85
Enterprise Value/Revenue
0.67
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-21.51%
Return on Equity (ttm)
-48.27%
Revenue (ttm)
9.28M
Net Income Avi to Common (ttm)
-53.73M
Diluted EPS (ttm)
-1.3800
Balance Sheet and Cash Flow
Total Cash (mrq)
135.3M
Total Debt/Equity (mrq)
35.26%
Levered Free Cash Flow (ttm)
-25.31M
Research Analysis: HOWL
View MoreCompany Insights: HOWL
HOWL does not have Company Insights